sulforaphane has been researched along with Obesity in 19 studies
sulforaphane: from Cardaria draba L.
sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Using a murine model of obesity-induced glucose dysregulated pregnancy, we demonstrate that NRF2 activation by maternal sulforaphane (SFN) supplementation normalizes NRF2-linked NQO1, GCL and CuZnSOD expression in maternal and fetal liver placental and fetal heart tissue by gestational day 17." | 8.31 | Sulforaphane induced NRF2 activation in obese pregnancy attenuates developmental redox imbalance and improves early-life cardiovascular function in offspring. ( Bowe, J; Chapple, SJ; Ehler, E; Mann, GE; Morris, JK; Psefteli, PM; Smith, L; Taylor, PD, 2023) |
| " Although sulforaphane (SFN), a natural HDAC inhibitor, has been reported to alleviate obesity in humans and mice, the specific mechanisms and how HDACs contribute to SFN's anti-obesity effects remain unclear." | 8.31 | Sulforaphane Mitigates High-Fat Diet-Induced Obesity by Enhancing Mitochondrial Biogenesis in Skeletal Muscle via the HDAC8-PGC1α Axis. ( Hur, G; Kim, J; Kim, JE; Kim, JH; Kim, JR; Lee, KW; Lee, TK; Park, JHY; Yang, H, 2023) |
| "The present study evaluated the anti-obesity effect of sulforaphane (SFN) and glucoraphanin (GRN) in broccoli leaf extract (BLE) on 3T3-L1 adipocytes and ob/ob mice." | 8.12 | Anti-obesity effect of sulforaphane in broccoli leaf extract on 3T3-L1 adipocytes and ob/ob mice. ( Dayarathne, LA; Dinh, DTT; Han, CH; Jee, Y; Mihindukulasooriya, SP; Natraj, P; Rajan, P; Ranaweera, SS, 2022) |
| "The phytochemical sulforaphane (SFN) has been studied for its potential anti-obesity effect, but neither its molecular targets nor its interaction with the antimalarial drug chloroquine (CQ) has been fully delineated." | 8.12 | Chloroquine modulates the sulforaphane anti-obesity mechanisms in a high-fat diet model: Role of JAK-2/ STAT-3/ SOCS-3 pathway. ( Abdallah, DM; Ali, MA; Ashmawy, AI; El-Abhar, HS, 2022) |
| " Nevertheless, the vasoprotective role of SFN has not been examined in the setting of obesity characterized by hyperleptinemia and insulin resistance." | 7.83 | Sulforaphane improves dysregulated metabolic profile and inhibits leptin-induced VSMC proliferation: Implications toward suppression of neointima formation after arterial injury in western diet-fed obese mice. ( Gameil, NM; Jun, JY; Pichavaram, P; Segar, L; Shawky, NM; Shehatou, GS; Suddek, GM, 2016) |
| "Obesity is linked to the onset of many diseases such as diabetes mellitus, cardiovascular diseases and cancer, among others." | 6.58 | Potential effects of sulforaphane to fight obesity. ( Antunes, LM; Colaço, B; Martins, T; Oliveira, PA; Pires, MJ; Rosa, E; Venâncio, C, 2018) |
| "Obesity is associated with metabolic disorders." | 5.40 | Sulforaphane attenuates obesity by inhibiting adipogenesis and activating the AMPK pathway in obese mice. ( Choi, KM; Hong, JT; Kim, SJ; Kim, W; Lee, MK; Lee, YM; Lee, YS; Shin, KO; Yoo, HS; Yu, JY; Yun, YP, 2014) |
| " Using a murine model of obesity-induced glucose dysregulated pregnancy, we demonstrate that NRF2 activation by maternal sulforaphane (SFN) supplementation normalizes NRF2-linked NQO1, GCL and CuZnSOD expression in maternal and fetal liver placental and fetal heart tissue by gestational day 17." | 4.31 | Sulforaphane induced NRF2 activation in obese pregnancy attenuates developmental redox imbalance and improves early-life cardiovascular function in offspring. ( Bowe, J; Chapple, SJ; Ehler, E; Mann, GE; Morris, JK; Psefteli, PM; Smith, L; Taylor, PD, 2023) |
| "The present study evaluated the anti-obesity effect of sulforaphane (SFN) and glucoraphanin (GRN) in broccoli leaf extract (BLE) on 3T3-L1 adipocytes and ob/ob mice." | 4.12 | Anti-obesity effect of sulforaphane in broccoli leaf extract on 3T3-L1 adipocytes and ob/ob mice. ( Dayarathne, LA; Dinh, DTT; Han, CH; Jee, Y; Mihindukulasooriya, SP; Natraj, P; Rajan, P; Ranaweera, SS, 2022) |
| "Chronic low-grade systemic inflammation (SI), including activation of the NLRP3 inflammasome, is a feature of obesity, associated with increased circulating saturated fatty acids, such as palmitic acid (PA), and bacterial endotoxin lipopolysaccharide (LPS)." | 4.12 | Sulforaphane reduces pro-inflammatory response to palmitic acid in monocytes and adipose tissue macrophages. ( Baines, KJ; Berthon, BS; Eslick, S; Gately, M; Guilleminault, L; Karihaloo, C; Williams, EJ; Wood, LG; Wright, T, 2022) |
| "Diet-induced obesity (DIO) is commonly associated with hyperleptinemia and leptin resistance." | 3.88 | Sulforaphane improves leptin responsiveness in high-fat high-sucrose diet-fed obese mice. ( Segar, L; Shawky, NM, 2018) |
| " Nevertheless, the vasoprotective role of SFN has not been examined in the setting of obesity characterized by hyperleptinemia and insulin resistance." | 3.83 | Sulforaphane improves dysregulated metabolic profile and inhibits leptin-induced VSMC proliferation: Implications toward suppression of neointima formation after arterial injury in western diet-fed obese mice. ( Gameil, NM; Jun, JY; Pichavaram, P; Segar, L; Shawky, NM; Shehatou, GS; Suddek, GM, 2016) |
| " However, species, disease model, duration, SFN dosage as well as route of administration did not explain the heterogeneity among studies." | 2.72 | Sulforaphane ameliorates lipid profile in rodents: an updated systematic review and meta-analysis. ( Du, K; Fan, Y; Li, D, 2021) |
| " The present study aims to test a dietary strategy, dietary supplementation with a high dose of vitamin D (VD) or its combination with sulforaphane (SFN) to inhibit intestinal inflammation and obesity-associated tumorigenesis." | 1.51 | The Prevention of a High Dose of Vitamin D or Its Combination with Sulforaphane on Intestinal Inflammation and Tumorigenesis in Apc ( Frederick, AM; Guo, C; Jin, Y; Li, J; Liu, Z; Wood, RJ; Xiao, H, 2019) |
| "Sulforaphane was subcutaneously injected at a dose of 0." | 1.51 | Sulforaphane ameliorates high-fat diet-induced spermatogenic deficiency in mice†. ( Hu, X; Huang, XX; Mu, Y; Yang, J; Yin, L; Yin, TL, 2019) |
| "Obesity is associated with metabolic disorders." | 1.40 | Sulforaphane attenuates obesity by inhibiting adipogenesis and activating the AMPK pathway in obese mice. ( Choi, KM; Hong, JT; Kim, SJ; Kim, W; Lee, MK; Lee, YM; Lee, YS; Shin, KO; Yoo, HS; Yu, JY; Yun, YP, 2014) |
| "Obesity and insulin resistance are the key factors underlying the etiology of major health problems such as hypertension, diabetes and stroke." | 1.39 | Chronic sulforaphane oral treatment accentuates blood glucose impairment and may affect GLUT3 expression in the cerebral cortex and hypothalamus of rats fed with a highly palatable diet. ( Brum, LM; de Assis, AM; Hansen, F; Moreira, JD; Perry, ML; Riboldi, BP; Souza, CG; Souza, DG; Souza, DO, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (47.37) | 24.3611 |
| 2020's | 10 (52.63) | 2.80 |
| Authors | Studies |
|---|---|
| Ranaweera, SS | 1 |
| Natraj, P | 1 |
| Rajan, P | 1 |
| Dayarathne, LA | 1 |
| Mihindukulasooriya, SP | 1 |
| Dinh, DTT | 1 |
| Jee, Y | 1 |
| Han, CH | 1 |
| Williams, EJ | 1 |
| Guilleminault, L | 1 |
| Berthon, BS | 1 |
| Eslick, S | 1 |
| Wright, T | 1 |
| Karihaloo, C | 1 |
| Gately, M | 1 |
| Baines, KJ | 1 |
| Wood, LG | 1 |
| Çakır, I | 1 |
| Lining Pan, P | 1 |
| Hadley, CK | 1 |
| El-Gamal, A | 1 |
| Fadel, A | 1 |
| Elsayegh, D | 1 |
| Mohamed, O | 1 |
| Rizk, NM | 1 |
| Ghamari-Langroudi, M | 1 |
| Ashmawy, AI | 1 |
| El-Abhar, HS | 1 |
| Abdallah, DM | 1 |
| Ali, MA | 1 |
| Psefteli, PM | 1 |
| Morris, JK | 1 |
| Ehler, E | 1 |
| Smith, L | 1 |
| Bowe, J | 1 |
| Mann, GE | 1 |
| Taylor, PD | 1 |
| Chapple, SJ | 1 |
| Yang, H | 1 |
| Hur, G | 1 |
| Lee, TK | 1 |
| Kim, JE | 1 |
| Kim, JH | 1 |
| Kim, JR | 1 |
| Kim, J | 1 |
| Park, JHY | 1 |
| Lee, KW | 1 |
| Isaacson, RH | 1 |
| Beier, JI | 1 |
| Khoo, NK | 1 |
| Freeman, BA | 1 |
| Freyberg, Z | 1 |
| Arteel, GE | 1 |
| Lu, Y | 1 |
| Zhang, Y | 1 |
| Lou, Y | 1 |
| Cui, W | 1 |
| Miao, L | 1 |
| Clifford, T | 1 |
| Acton, JP | 1 |
| Cocksedge, SP | 1 |
| Davies, KAB | 1 |
| Bailey, SJ | 1 |
| Du, K | 1 |
| Fan, Y | 1 |
| Li, D | 1 |
| Axelsson, AS | 1 |
| Tubbs, E | 1 |
| Mecham, B | 1 |
| Chacko, S | 1 |
| Nenonen, HA | 1 |
| Tang, Y | 1 |
| Fahey, JW | 1 |
| Derry, JMJ | 1 |
| Wollheim, CB | 1 |
| Wierup, N | 1 |
| Haymond, MW | 1 |
| Friend, SH | 1 |
| Mulder, H | 1 |
| Rosengren, AH | 1 |
| Martins, T | 1 |
| Colaço, B | 1 |
| Venâncio, C | 1 |
| Pires, MJ | 1 |
| Oliveira, PA | 1 |
| Rosa, E | 1 |
| Antunes, LM | 1 |
| Shawky, NM | 2 |
| Segar, L | 2 |
| Li, J | 1 |
| Frederick, AM | 1 |
| Jin, Y | 1 |
| Guo, C | 1 |
| Xiao, H | 1 |
| Wood, RJ | 1 |
| Liu, Z | 1 |
| Mu, Y | 1 |
| Yin, TL | 1 |
| Huang, XX | 1 |
| Hu, X | 1 |
| Yin, L | 1 |
| Yang, J | 1 |
| Souza, CG | 1 |
| Riboldi, BP | 1 |
| Hansen, F | 1 |
| Moreira, JD | 1 |
| Souza, DG | 1 |
| de Assis, AM | 1 |
| Brum, LM | 1 |
| Perry, ML | 1 |
| Souza, DO | 1 |
| Choi, KM | 1 |
| Lee, YS | 1 |
| Kim, W | 1 |
| Kim, SJ | 1 |
| Shin, KO | 1 |
| Yu, JY | 1 |
| Lee, MK | 1 |
| Lee, YM | 1 |
| Hong, JT | 1 |
| Yun, YP | 1 |
| Yoo, HS | 1 |
| Xue, H | 1 |
| Li, Y | 1 |
| Liang, B | 1 |
| Wang, S | 1 |
| Pichavaram, P | 1 |
| Shehatou, GS | 1 |
| Suddek, GM | 1 |
| Gameil, NM | 1 |
| Jun, JY | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Clinical Trial With Broccoli Sprout Extract to Patients With Type 2 Diabetes[NCT02801448] | Phase 2 | 103 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for sulforaphane and Obesity
| Article | Year |
|---|---|
The effect of dietary phytochemicals on nuclear factor erythroid 2-related factor 2 (Nrf2) activation: a systematic review of human intervention trials.
Topics: Adult; Aged; Antioxidants; Bias; Curcumin; Diabetes Mellitus, Type 2; Humans; Isothiocyanates; Middl | 2021 |
Sulforaphane ameliorates lipid profile in rodents: an updated systematic review and meta-analysis.
Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus; Isothiocyanates; Lipids; Mice; Non-alcoholic Fa | 2021 |
Potential effects of sulforaphane to fight obesity.
Topics: Animals; Anti-Obesity Agents; Brassica; Humans; Isothiocyanates; Obesity; Plant Extracts; Sulfoxides | 2018 |
16 other studies available for sulforaphane and Obesity
| Article | Year |
|---|---|
Anti-obesity effect of sulforaphane in broccoli leaf extract on 3T3-L1 adipocytes and ob/ob mice.
Topics: 3T3-L1 Cells; Adipocytes; Adipocytes, White; AMP-Activated Protein Kinases; Animals; Anti-Obesity Ag | 2022 |
Sulforaphane reduces pro-inflammatory response to palmitic acid in monocytes and adipose tissue macrophages.
Topics: Adipose Tissue; Humans; Inflammasomes; Inflammation; Interleukin-1beta; Isothiocyanates; Lipopolysac | 2022 |
Sulforaphane reduces obesity by reversing leptin resistance.
Topics: Animals; Inflammation; Isothiocyanates; Leptin; Mice; Mice, Inbred C57BL; NF-E2-Related Factor 2; Ob | 2022 |
Chloroquine modulates the sulforaphane anti-obesity mechanisms in a high-fat diet model: Role of JAK-2/ STAT-3/ SOCS-3 pathway.
Topics: Animals; Chloroquine; Diet, High-Fat; Isothiocyanates; Janus Kinase 2; Liver; Obesity; Random Alloca | 2022 |
Sulforaphane induced NRF2 activation in obese pregnancy attenuates developmental redox imbalance and improves early-life cardiovascular function in offspring.
Topics: Animals; Female; Humans; Isothiocyanates; Male; Mice; Myocytes, Cardiac; NF-E2-Related Factor 2; Obe | 2023 |
Sulforaphane Mitigates High-Fat Diet-Induced Obesity by Enhancing Mitochondrial Biogenesis in Skeletal Muscle via the HDAC8-PGC1α Axis.
Topics: Animals; Diet, High-Fat; Histone Deacetylases; Humans; Mice; Muscle, Skeletal; Obesity; Organelle Bi | 2023 |
Olanzapine-induced liver injury in mice: aggravation by high-fat diet and protection with sulforaphane.
Topics: Animals; Antioxidants; Antipsychotic Agents; Body Weight; Chemical and Drug Induced Liver Injury; Di | 2020 |
Sulforaphane suppresses obesity-related glomerulopathy-induced damage by enhancing autophagy via Nrf2.
Topics: Animals; Autophagy; Cells, Cultured; Isothiocyanates; Kidney Diseases; Kidney Glomerulus; Male; Mice | 2020 |
Sulforaphane reduces hepatic glucose production and improves glucose control in patients with type 2 diabetes.
Topics: Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Female; Glucose; Glycated Hemoglobin; | 2017 |
Sulforaphane improves leptin responsiveness in high-fat high-sucrose diet-fed obese mice.
Topics: Animals; Body Weight; Diet, High-Fat; Eating; Isothiocyanates; Leptin; Male; Mice; Mice, Inbred C57B | 2018 |
The Prevention of a High Dose of Vitamin D or Its Combination with Sulforaphane on Intestinal Inflammation and Tumorigenesis in Apc
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents; Autophagy; beta Catenin; Diet, High-Fat; En | 2019 |
Sulforaphane ameliorates high-fat diet-induced spermatogenic deficiency in mice†.
Topics: Adult; AMP-Activated Protein Kinases; Animals; Case-Control Studies; Cells, Cultured; Diet, High-Fat | 2019 |
Chronic sulforaphane oral treatment accentuates blood glucose impairment and may affect GLUT3 expression in the cerebral cortex and hypothalamus of rats fed with a highly palatable diet.
Topics: Animals; Blood Glucose; Cerebral Cortex; Glucose Transporter Type 3; Humans; Hypothalamus; Insulin R | 2013 |
Sulforaphane attenuates obesity by inhibiting adipogenesis and activating the AMPK pathway in obese mice.
Topics: Adenylate Kinase; Adipogenesis; Animals; Body Weight; Cholesterol; Enzyme Activation; Isothiocyanate | 2014 |
[Protective effects of sulforaphane on the oxidative damage of kidney mitochondria complex in obese rats induced by high-fat diet].
Topics: Animals; Diet; Diet, High-Fat; Isothiocyanates; Kidney; Male; Mitochondria; Obesity; Oxidative Stres | 2014 |
Sulforaphane improves dysregulated metabolic profile and inhibits leptin-induced VSMC proliferation: Implications toward suppression of neointima formation after arterial injury in western diet-fed obese mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Obesity Agents; Anticarcinogenic Agents; Anti | 2016 |